Separation and Distribution AgreementSeparation and Distribution Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • Delaware
This Separation and Distribution Agreement (this “Agreement”), dated as of [ ], 2008, is entered into by and between PDL BioPharma, Inc., a Delaware corporation (“PDL”), and Facet Biotech Corporation, a Delaware corporation (“Facet”) (each a “Party” and collectively, the “Parties”). Capitalized terms used herein and not otherwise defined shall have the respective meanings assigned to them in Article I.
CONFIDENTIAL PROVISIONS REDACTED COLLABORATION AGREEMENTCollaboration Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • California
THIS COLLABORATION AGREEMENT (the “Agreement”) is entered into as of September 12, 2005 (the “Effective Date”) by and between Protein Design Labs, Inc., a Delaware corporation having its offices at 34801 Campus Drive, Fremont, California 94555 (“PDL”), and Biogen Idec MA Inc., a Massachusetts corporation having offices at 14 Cambridge Center, Cambridge, Massachusetts 02142 (“Biogen Idec”). PDL and Biogen Idec may each be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
COLLABORATION AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC. AND BRISTOL-MYERS SQUIBB COMPANY AUGUST 18, 2008Collaboration Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations
THIS COLLABORATION AGREEMENT (the “Agreement”) is made and entered into as of August 18, 2008 (the “Execution Date”) by and between PDL Biopharma, Inc., a Delaware corporation having its principal place of business at 1400 Seaport Blvd., Redwood City, CA 94063 (“PDL”) and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”), effective as of the Effective Date (as defined in Section 12.6), except for Article 10 and Section 12.6, which shall be effective as of the Execution Date. PDL and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENTClinical Drug Substance Supply Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • New York
THIS CLINICAL DRUG SUBSTANCE SUPPLY AGREEMENT (this “Agreement”) is effective as of the Effective Date (as defined below) and is by and between GMN, Inc., a Delaware corporation and a wholly owned subsidiary of Genmab A/S, a corporation organized under the laws of Denmark, having its principal place of business at 9450 Winnetka Avenue N, Brooklyn Park, MN (“GMN”) and PDL BioPharma, Inc., a corporation organized under the laws of Delaware, having its principal place of business at 1400 Seaport Boulevard, Redwood City, CA 94063 (“PDL”).
LICENSE AGREEMENT BY AND BETWEEN PROTEIN DESIGN LABS, INC. AND HUMAN GENOME SCIENCES, INC. December 15, 2005License Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • New York
This License Agreement (“Agreement”) is entered into as of December 15, 2005 (the “Effective Date”) by and between PROTEIN DESIGN LABS, INC., having its principal offices at 34801 Campus Drive, Fremont, CA 94555 USA (“PDL”), and HUMAN GENOME SCIENCES, INC., having its principal offices at 14200 Shady Grove Road, Rockville, MD 20850 USA (“HGS”). PDL and HGS are each individually referred to as a “Party,” and collectively as the “Parties.”
CONFIDENTIAL PROVISIONS REDACTED ASSET PURCHASE AGREEMENT BY AND BETWEEN PDL BIOPHARMA, INC., a Delaware corporation andAsset Purchase Agreement • December 4th, 2008 • Facet Biotech Corp • Pharmaceutical preparations • California
This Asset Purchase Agreement (this “Agreement”) is entered into as of February 4, 2008 (the “Effective Date”) between PDL BioPharma, Inc., a Delaware corporation (“Seller”) and EKR Therapeutics, Inc., a Delaware corporation (“Buyer”).
